The Cancer Research UK Convergence Science Centre was established as a strategic partnership between Imperial College London and The Institute of Cancer Research, London. 

 

The mission of the Centre is to bring together engineering, physical sciences, life sciences and medicine to develop innovative ways to address challenges in cancer research to benefit cancer patients. This is achieved through multidisciplinary collaborations that integrate otherwise distinct approaches to co-create new tools, technologies and methodologies. It is underpinned by a Major Centre award from Cancer Research UK, which provides the funding to create step changes in cancer research to address unmet medical needs in all cancers, particularly those that are hard to treat.

 

Directed by Professor Axel Behrens, the Convergence Science Centre brings together two of the UK’s leading academic research organisations to create a closely integrated and sustainable partnership. ICR’s vision (to ‘make the discoveries that defeat cancer’) and Imperial’s (‘to achieve enduring excellence in research and education in science, engineering, medicine and business for the benefit of society’) are highly complementary – a key factor that underpins our powerful and synergistic strategic alliance.


With a remit to work across the entirety of both the ICR and Imperial, the Centre fosters new opportunities for collaboration between researchers at the two institutions and to support the clinical translation of novel cancer technologies and therapeutics. Over the first grant period, the aim is to build the collaborative network, leverage additional funding and establish key translational infrastructure to accelerate clinical implementation of new approaches.

 

Since 2022, the Centre has merged with the CRUK Imperial Centre and the CRUK ICR Centre, giving rise to renewed CRUK Convergence Science Centre. Our mission remains to accelerate the development of ground-breaking cancer technologies across our partnering institutions. The CRUK Convergence Science Centre will spearhead pioneering research, with a strong emphasis on implementation and clinical adoption. Our collective efforts aim to translate discoveries into tangible benefits for patients and healthcare providers.

 

Our founding co-directors

 

In 2016, the ICR and Imperial came together to establish the Cancer Research Centre of Excellence under the direction of Professor Paul Workman and Professor The Lord Ara Darzi of Denham. This partnership was formed to create critical mass for multidisciplinary inter-institutional collaboration, to improve quality of life for cancer patients. Thanks to the leadership and vision of Professors Workman and Darzi, the Cancer Research Centre of Excellence laid the foundations for the successful award of a CRUK Major Centre and the establishment of the Cancer Research UK Convergence Science Centre.

 

 

Developing 
innovative ways

to address the toughest 

challenges in cancer 

Cancer drug discovery technologies get a £4.5m boost

Oct 5, 2020, 14:15 PM by User Not Found
Improving imaging technologies for cancer drug discovery with a £4.5 m Cancer Research UK Accelerator Award collaboration between Imperial College London, the Francis Crick Institute, the University of Edinburgh, the Institute of Cancer Research and the Instituto de Recerca Biomedica in Barcelona.


 

Imperial academics will lead a project to improve imaging technologies for cancer drug discovery, funded by CRUK and European partners.

 

The funding is part of the Cancer Research UK Accelerator Awards programme, which provides five years of funding for international projects.

 

The £4.5m project will be led by Professor Paul French from the Department of Physics at Imperial, with collaborators across the Faculties of Natural Sciences and Medicine, and partners in the Francis Crick Institute, the University of Edinburgh, the Institute of Cancer Research and the Instituto de Recerca Biomedica in Barcelona.

 

The project led by Imperial is also part of the CRUK Convergence Science Centre, a partnership between Imperial and the Institute of Cancer Research. The Centre aims to bring together engineers and physical scientists with cancer researchers to develop new tools and technologies to address unmet needs in cancer.

 

Read more here

Load more comments
Comment by from

Cancer drug discovery technologies get a £4.5m boost

Oct 5, 2020, 14:15 PM by User Not Found
Improving imaging technologies for cancer drug discovery with a £4.5 m Cancer Research UK Accelerator Award collaboration between Imperial College London, the Francis Crick Institute, the University of Edinburgh, the Institute of Cancer Research and the Instituto de Recerca Biomedica in Barcelona.


 

Imperial academics will lead a project to improve imaging technologies for cancer drug discovery, funded by CRUK and European partners.

 

The funding is part of the Cancer Research UK Accelerator Awards programme, which provides five years of funding for international projects.

 

The £4.5m project will be led by Professor Paul French from the Department of Physics at Imperial, with collaborators across the Faculties of Natural Sciences and Medicine, and partners in the Francis Crick Institute, the University of Edinburgh, the Institute of Cancer Research and the Instituto de Recerca Biomedica in Barcelona.

 

The project led by Imperial is also part of the CRUK Convergence Science Centre, a partnership between Imperial and the Institute of Cancer Research. The Centre aims to bring together engineers and physical scientists with cancer researchers to develop new tools and technologies to address unmet needs in cancer.

 

Read more here

Load more comments
Comment by from